The Italian Medicines Agency (AIFA) recognizes GH therapy for a number of conditions, including but not limited GHD, SHOX haploinsufficiency, Turner syndrome, and children born small for gestational age; however, ISS is not formally included among reimbursed indications. Here, GH1 is linked to Turner syndrome.